ELIZABETH PRINCE-COLEMAN: Open Payments
NPI 1316378748 · AUGUSTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$536 in 24 payments from 11 companies in 2025. Trend: 2023 $530 · 2024 $200 · 2025 $536
Food & beverage: $536
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $85 |
| Amneal Pharmaceuticals LLC | 3 | $76 |
| Averitas Pharma Inc. | 3 | $74 |
| ACADIA Pharmaceuticals Inc | 3 | $61 |
| Merz Pharmaceuticals, LLC | 3 | $58 |
| Biogen, Inc. | 2 | $53 |
| UCB, Inc. | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Alexion Pharmaceuticals, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
Products named: INGREZZA, CREXONT, QUTENZA, NUPLAZID, INBRIJA, SKYCLARYS, Zilbrysq, AUSTEDO XR.
Industry payments across GA — which companies pay providers there.
